Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAM-H2
- Development stage
- Phase 2
- Lead developer
- Precirix
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CAM-H2 is a targeted radionuclide therapeutic drug (TRNT) designed for the treatment of HER2-expressing cancers, including metastatic breast cancer and gastric/gastroesophageal cancer. It consists of a single-domain antibody fragment (sdAb), derived from camelid antibodies, that specifically binds to the human epidermal growth factor receptor 2 (HER2). This sdAb is covalently linked to the radioactive isotope iodine-131 via the SGMIB linker. Upon administration, CAM-H2 delivers beta radiation directly to HER2-positive tumor cells while minimizing exposure to healthy tissues. The drug has demonstrated high specificity and retention in HER2+ tumors in imaging studies and has shown a favorable safety profile in phase I clinical trials. It is currently being evaluated in phase I/II clinical studies for patients who have relapsed or are refractory to existing anti-HER2 therapies[1][4][5][6][8]. Developer: Precirix Manufacturer: Evergreen Theragnostics
- Other names
- VHH1VHH-1VHH 1CAM-H2CAM-H-2CAM-H 2
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on CAM-H2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAM-H2.